The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Istari Oncology; Orbus Therapeutics
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Orbus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - AU 2019247039 NEOADJUVANT CANCER TREATMENT; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; Canada NEOADJUVANT CANCER TREATMENT; China NEOADJUVANT CANCER TREATMENT; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2020-554198 NEOADJUVANT CANCER TREATMENT; PCT/US2019/025402 NEOADJUVANT CANCER TREATMENT; South Korea 10-2020-7031272 NEOADJUVANT CANCER TREATMENT; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; US 16/086,735 SEQUENTIAL ANTI-CANCER TREATMENT; US 16/505,771 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/016,699 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/044,645 NEOADJUVANT CANCER TREATMENT; US 62/651,470; US 62/823,277 NEOADJUVANT CANCER TREATMENT
 
Vidyalakshmi Chandramohan
No Relationships to Disclose
 
Daniel B Landi
No Relationships to Disclose
 
Margaret O. Johnson
No Relationships to Disclose
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Janssen; Lilly; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Katherine B. Peters
Consulting or Advisory Role - Sapience Therapeutics; SERVIER; Vivacitas Oncology
Research Funding - Abbvie; Agios; BioMimetix; Novocure; Sapience Therapeutics; SERVIER
Other Relationship - Eisai Europe
 
Justin Low
No Relationships to Disclose
 
James Emmett Herndon
No Relationships to Disclose
 
Stevie Threatt
No Relationships to Disclose
 
Chevelle A. Bullock
No Relationships to Disclose
 
Eric S. Lipp
No Relationships to Disclose
 
John H. Sampson
Stock and Other Ownership Interests - Annias Immunotherapeutics; ISTARI
Consulting or Advisory Role - Annias Immunotherapeutics; Insera Health; Medicenna
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics - Equity, Licensed IP; Istari Oncology - Equity, Licensed IP; Neuronium - Equity, Optioned IP
 
Allan H. Friedman
Stock and Other Ownership Interests - ISTARI Oncology
 
Henry S. Friedman
Stock and Other Ownership Interests - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Consulting or Advisory Role - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
 
David M. Ashley
Stock and Other Ownership Interests - Diverse Biotech; MAIA Biotechnology
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; MAIA Biotechnology
Patents, Royalties, Other Intellectual Property - Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/787,508 filed January 2, 2019 Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/620,577 filed January 23, 2018
 
David Knorr
Honoraria - Pfizer
Consulting or Advisory Role - Shoreline Biosciences
Research Funding - Pfizer
 
Darell D. Bigner
Leadership - ISTARI Oncology
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Activation of Dendritic Cells with PVSRIPO (PCT/US17/039953); Combination Oncolytic Poliovirus and Immunotoxin (US 62/507877); Combination Therapy for Cancer Using Oncolytic Poliovirus (PCT/US17/023148); Detection of CD155, PVR (PCT/US17/054733); Enterovirus-IRES Insertion Expression Vector (US 7,968,086); Method of Treating Solid Tumor w/Oncolytic Poliovirus (US 15/428510 ); PVSRIPO-Checkpoint Inhibitor Combination Therapy (PCT/US16/057023)